CGTX
Cognition Therapeutics Inc
NASDAQ: CGTX · HEALTHCARE · BIOTECHNOLOGY
$0.92
+1.65% today
Updated 2026-07-30
Market cap
$85.94M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.23
Dividend yield
—
52W range
$1 – $4
Volume
1.6M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-5.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$3.50
+282.10%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -5.05 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.54M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $757000.00 | $-25.79M | $-33.97M | $-23.49M | $-4.57M |
| EPS | — | — | — | — | $-0.23 |
| Free cash flow | $-18.70M | $-16.16M | $-28.48M | $-24.59M | $-5.54M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Cognition Therapeutics Inc trades at $0.92. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -5.05, it sits in the distress.
Frequently asked questions
What is Cognition Therapeutics Inc's stock price?
Cognition Therapeutics Inc (CGTX) trades at $0.92.
Is Cognition Therapeutics Inc overvalued?
Cognition Therapeutics Inc carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Cognition Therapeutics Inc (CGTX)?
The 12-month analyst consensus target is $3.50, about 282.1% above the current $0.92. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Cognition Therapeutics Inc's Altman Z-Score is -5.05, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-65.45%
Beta1.75
50D MA$1.18
200D MA$1.30
Shares out0.09B
Float0.08B
Short ratio—
Avg volume1.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—